Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Study Finds Social And Economic Factors Play Major Role In Determining Who Gets Bariatric Surgery
Less than one-half of one percent (0.4%) of the 22 million people in the U.S. who are medically eligible for bariatric surgery actually get the surgery, and those who do are most likely to be white females with higher incomes and covered by private health insurance, according to a new study presented here at the 26th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS).
generic viagra online
Variation In Prostate Stem Cell Antigen Gene Raises Bladder Cancer Risk
Researchers have pinpointed a specific gene variation that causes increased risk of urinary bladder cancer, according to a scientific team led by The University of Texas M. D. Anderson Cancer Center.
News of the day
Adhering To Healthy Lifestyle Habits Associated With Reduced Lifetime Risk Of Heart Failure
Men who exercised regularly, drank moderately, did not smoke, who were not overweight and had a diet that included cereal and fruits and vegetables had a lower lifetime risk of heart failure, according to a study in the July 22/29 issue of JAMA.
Endocrinology

Gilead Sciences, Tibotec To Develop Second Once-Daily HIV Treatment

Foster City, Calif.-based Gilead Sciences on Thursday said it has entered into a license and collaboration agreement with Johnson and Johnson subsidiary Tibotec Pharmaceuticals for the development and commercialization of a new once-daily fixed-dose treatment for HIV, the San Francisco Business Times reports. The FDA approved the first once-daily HIV treatment Atripla in 2006 (7/16). The new antiretroviral drug would contain Tibotec"s experimental non-nucleoside reverse transcriptase inhibitor, known as TMC278, and Gilead"s combination pill, Truvada. Kevin Young, head of commercial operations at Gilead "said the new combination pill, along with Gilead"s experimental "quad" pill, will be used for newly-diagnosed patients, with physicians reluctant to change therapy for patients who are responding well to Atripla," Reuters reports. Young said the drug is expected to reach the market in 2011 (Beasley, 7/16). This information was reprinted from dailyreports.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily U.S. HIV/AIDS Report, search the archives and sign up for email delivery at dailyreports.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009